Metsera, a clinical-stage biotechnology company focused on developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for treating obesity and related conditions, has announced the pricing of its initial public offering. The company is offering 15,277,778 shares of its common stock at $18.00 per share, expecting to raise approximately $275 million before deducting underwriting discounts, commissions, and offering expenses. Metsera’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “MTSR” on January 31, 2025. The offering closed on February 3, 2025, subject to customary closing conditions. The company has also granted underwriters a 30-day option to purchase an additional 2,291,666 shares at the initial price, excluding fees and commissions.
BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, and Cantor are serving as joint bookrunners for the offering. The Securities and Exchange Commission has approved Metsera’s registration statement on Form S-1, which became effective on January 30, 2025. The offering is being conducted solely through a prospectus. With this IPO, Metsera aims to advance its research and development efforts in addressing obesity and related health conditions.
